Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. By investing over $77M, HLB Co., LTD, a global pharmaceutical company focused on developing novel cancer drugs, ITI is well-positioned to accelerate its immuno-oncology platform, in particular glioblastoma multiforme, and rapidly advance other key candidates in our pipeline, including the most recent initiative into infectious diseases with development of its vaccine candidate for COVID-19. All program areas are driven by ITI?s UNITE? platform .